Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
BRCA1/2-mutated patients benefit from olaparib, but with variations according to the mutation type and FDs. BRCA1-mutated patients in the RING or BRCT and BRCA2-mutated in the RAD51-BD have the greatest benefit. Patients with missense mutations, especially those with p.(Ala1708Glu), have the most significant advantage from maintenance with PARPi.
Authors
- Eloisa Arbustini (ORCID: https://orcid.org/0000-0003-2948-7994)
- M T Perri
- Mariagrazia Distefano (ORCID: https://orcid.org/0000-0001-7473-702X)
- Lucia Musacchio (ORCID: https://orcid.org/0000-0003-3780-5630)
- Cristina Angela Camnasio
- Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
- Emilia Giudice
- Maria Gabriella Ferrandina
- S M Boccia
- Vanda Salutari (ORCID: https://orcid.org/0009-0007-1104-7866)
- D. Lorusso
- Carolina Maria Sassu (ORCID: https://orcid.org/0000-0002-1702-5859)
- Cristina Marchetti (ORCID: https://orcid.org/0000-0002-9019-3779)
- Marta Seca (ORCID: https://orcid.org/0000-0003-1944-0842)
- Lorena Incorvaia (ORCID: https://orcid.org/0000-0002-1199-7286)
- Chiara Cassani (ORCID: https://orcid.org/0000-0002-8055-5086)
- Robert Fruscio (ORCID: https://orcid.org/0000-0001-5688-2194)
- Laura Vertechy (ORCID: https://orcid.org/0000-0002-1155-3888)
- Anna Fagotti (ORCID: https://orcid.org/0000-0001-5579-335X)
- Camilla Nero (ORCID: https://orcid.org/0000-0002-4442-4046)
- Angelo Minucci (ORCID: https://orcid.org/0000-0002-0833-4334)
- Diana Giannarelli (ORCID: https://orcid.org/0000-0002-6085-1195)
- Antonio Dello Russo (ORCID: https://orcid.org/0000-0002-4370-2008)
- Maria De Bonis (ORCID: https://orcid.org/0000-0001-5479-2144)
Institutions
- Humanitas University (IT)
- Agostino Gemelli University Polyclinic (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Milano-Bicocca (IT)
- University of Palermo (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104533
- Citations
- 12
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 12.54